BioSpace News Archive

MiNK Therapeutics (Nasdaq: INKT) today presented preclinical data demonstrating the potential of its novel FAP-CAR-iNKT candidate, MiNK-215, at the American Society of Gene and Cell Therapy (ASGCT) annual meeting.

HeartBeam, Inc. today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its HeartBeam AIMIGo™ System.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced new nonclinical data supporting the use of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) at the American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting in Los Angeles, California.

Abbott (NYSE: ABT) today announced its Assert-IQ™ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats.

Neurophet, an artificial intelligence (AI) solution company for brain disease, announced that the US Food and Drug Administration (FDA) 510(k) has cleared “Neurophet AQUA”.

inHEART, a privately-held medical device company delivering the world’s most advanced digital twin of the patient’s heart, announced that it has received CE certification under the new European Medical Device Regulation for its inHEART MODELS software suite that enables 3D visualization and analysis of anatomical structures for image-guided cardiac ablations.

Kiyatec, Inc., the leader in functional precision oncology, announced a new investment from the venture philanthropy arms of two leading brain tumor patient organizations.

Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announces today a publication describing new criteria for antibody-drug conjugate (ADC) development and preclinical efficacy of NAV-001 ADC against mesothelin-expressing tumor types.

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”), a nanotechnology company developing pre-clinical Targeted Hyperthermia Therapy for colorectal cancer, is pleased to announce the election as chair of the board

Justera Health Ltd. (CSE: VTAL) (OTCQB: SCRSF) (formerly ScreenPro Security Inc.) (“Justera” or the “Company”) is pleased to announce that it has successfully changed its name to “Justera Health Ltd.”